Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

Delayed Quote. Delayed  - 04/21 10:01:17 pm
121.76 USD   -0.09%
04/22 JOHNSON & JOHNS : Sun Sentinel Ira Winderman column
04/21DJFDA OKs Samsung Bioepis's biosimilar version of J&J's Remicade
04/21 The DOs and the DON’Ts of a media pitch
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Johnson & Johnson : J&J Cancer Drug Zytiga Now Backed For Publicly Funded Use In UK

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/16/2012 | 11:11am CEST

The U.K.'s health-care cost-effectiveness regulator Wednesday reversed an earlier decision and approved the publicly funded use of Johnson & Johnson's (JNJ) prostate-cancer pill Zytiga, after the U.S. company cut its price further.

Also known as abiraterone, Zytiga removes the prostate cancer tumor's supply of testosterone, preventing it from growing further and potentially extending a patient's life by more than three months. The medicine was rejected for use in the U.K. in February on grounds its terms of use wouldn't offer value for money.

Andrew Dillon, chief executive of the U.K.'s National Institute for Health and Clinical Excellence, or NICE, Wednesday said the manufacturer subsequently submitted fresh information, including a revised patient access scheme containing a deeper price discount to the National Health Service and more information about which patients would most benefit from its use and how many patients could receive the drug.

"These factors enabled the committee to revise its preliminary recommendation and now recommend the drug for use on the NHS," Dillon said in a statement. "It is an effective treatment, potentially extending life by more than three months, and it also allows patients to be treated at home as it can be taken orally."

Abiraterone costs GBP2,930 for a 30-day supply of 120 tablets. NICE didn't specify the size of the price cut offered by Johnson & Johnson.

Zytiga was approved by U.S. and European drug regulators last year. It is set to generate peak-year sales of $910 million.

-By Sten Stovall, Dow Jones Newswires; +44 207 842 9292; [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
04/22 JOHNSON & JOHNSON : Sun Sentinel Ira Winderman column
04/21DJFDA OKs Samsung Bioepis's biosimilar version of J&J's Remicade
04/21 The DOs and the DON’Ts of a media pitch
04/20 JOHNSON & JOHNSON : DePuy Synthes Acquires Tissue Regeneration System’s 3D..
04/20 JOHNSON & JOHNSON : Today's Research Reports on Stocks to Watch: Johnson & Johns..
04/20 UNILEVER : David Indo, co-founder of ID Comms, on media pitches, e-auctions and ..
04/19 JOHNSON & JOHNSON : Reports 2017 First Quarter Results
04/19 JOHNSON & JOHNSON : Says Pricing Competition Squeezed 1Q Sales
04/19 JOHNSON & JOHNSON : J&J revenue misses on lower-than-expected pharmaceutical sal..
04/19 JOHNSON & JOHNSON : Agloan-Stocks Fall on Weak Company Earnings
More news
Sector news : Pharmaceuticals - NEC
03:01a Becton Dickinson to acquire Bard for $24 billion
04/22DJNOVARTIS : Tests New Alzheimer's Drug on People Who Don't Have the Disease
04/21DJFDA OKs Samsung Bioepis's biosimilar version of J&J's Remicade
04/21 Teva's new asthma inhaler poses first competition for GSK's Advair
04/19DJSHIRE : Files 8K - Other Events
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
04/23 JOHNSON & JOHNSON : Modest Price Decline Presents Buying Opportunity
04/23 Baby DivHut Dividend Income Portfolio Update Q1 2017
04/23 1st Quarter Portfolio Results - Better Than Expected
04/21 FDA approves Merck biosimilar for immune-disorder drug Renflexis
04/21 JOHNSON & JOHNSON : Need Rock-Solid Dividend Growth? Look Here
Advertisement
Financials ($)
Sales 2017 75 714 M
EBIT 2017 23 390 M
Net income 2017 17 887 M
Debt 2017 6 597 M
Yield 2017 2,76%
P/E ratio 2017 18,57
P/E ratio 2018 16,68
EV / Sales 2017 4,45x
EV / Sales 2018 4,27x
Capitalization 330 078 M
More Financials
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 129 $
Spread / Average Target 5,7%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON5.69%330 078
ROCHE HOLDING LTD.8.21%217 624
PFIZER INC.3.57%200 330
NOVARTIS AG-1.08%192 857
MERCK & CO., INC.5.13%169 673
SANOFI7.10%114 121
More Results